GHRP-2: what the research shows
- By Reed Calder
- Last reviewed Nov 12, 2026
- 25 studies and official documents checked
In short
GHRP-2 (pralmorelin) is a lab-made six-amino-acid peptide that copies the signal of the hormone ghrelin and makes the pituitary release growth hormone. It is the only peptide in its family with an approved product, and that product, sold in Japan, is a single 100 microgram injection used as a test for growth hormone deficiency. In the study behind it, peak growth hormone averaged 84.6 micrograms per litre in 77 healthy people and 1.4 in 58 patients. In 7 lean men an infusion raised what they ate at a buffet by 35.9%. A 30-day infusion kept IGF-1 raised in older adults, but children’s IGF-1 did not rise over 8 months of injections. It also raises cortisol, ACTH and prolactin. It isn’t approved in the United States, the FDA lists safety concerns, and the World Anti-Doping Agency bans it at all times.
EvidenceCellAnimalHuman
GHRP-2 is sold online as a “peptide” for muscle, recovery, sleep and fat loss. This page covers what it is, the Japanese diagnostic product, what the human studies found over a single dose, a 30-day infusion and months of treatment in children, the appetite and hormone effects, and where it stands legally.
Names and forms you’ll see
| Name | What it is | Studied in people? |
|---|---|---|
| GHRP-2 | Growth hormone-releasing peptide 2, a lab-made peptide of six amino acids that includes one not found in nature, 2-naphthylalanine (FDA GSRS) | Yes |
| Pralmorelin | The international nonproprietary name for GHRP-2, with the development code KP-102 (FDA GSRS) | Same as GHRP-2 |
| GHRP Kaken 100 | The Japanese product: a single-dose vial of pralmorelin hydrochloride, 100 micrograms, for a diagnostic test (Japan label) | Yes, as a test |
| Pralmorelin hydrochloride | The salt form in the Japanese product, with a registry record of its own (FDA GSRS). The research papers we read don’t say which form was used | The product |
| “GHRP-2 peptide” | A search phrase and a sales label for the same compound | Same as GHRP-2 |
CAS numbers
A CAS number is a substance’s chemical registry number. Some “research” vials list it in place of a name. A different number usually means a different form, such as a salt, or a different substance. The base and the hydrochloride salt used in Japan have different registry numbers.
What GHRP-2 is
GHRP-2 belongs to the family of growth hormone releasing peptides discovered by Cyril Bowers; GHRP-6 was the first. It acts on the receptor for ghrelin, a hormone made mostly in the stomach, and makes the pituitary release growth hormone (GH) (Laferrère et al., 2005). The FDA notes that it contains an unnatural amino acid, which makes it harder to characterize (FDA, 2026).
In ten children given 1 microgram per kilogram into a vein, GHRP-2 left the blood with a half-life of about 33 minutes, and GH peaked about 25 minutes after the dose (Pihoker et al., 1998).
Other compounds in this group are hexarelin, ipamorelin and the non-peptide MK-677.
What has been studied
The Japanese diagnostic test
- The study behind it. In 77 healthy people and 58 patients whose GH peak was under 3 micrograms per litre on the standard insulin tolerance test, 100 micrograms of GHRP-2 was given into a vein after an overnight fast. Peak GH averaged 84.6 micrograms per litre in healthy people and 1.4 in patients. A cut-off of 15 micrograms per litre matched the standard test’s 3. Repeat tests agreed, and results were slightly lower in older people and in people with more body fat (Chihara et al., 2007).
- The Japanese label. The product is a 100 microgram vial for diagnosing growth hormone deficiency. Adults get 100 micrograms slowly into a vein on an empty stomach; children aged 4 to 17 get 2 micrograms per kilogram, up to 100 micrograms. It is contraindicated in pregnancy. Sales began in February 2005, and the label was last revised in July 2025 (Japan drug label).
Growth hormone and other hormones
- Against GHRH and hexarelin. In six young adults given 1 and 2 micrograms per kilogram into a vein, GHRP-2 and hexarelin gave similar, strong GH responses, both higher than growth-hormone-releasing hormone. Both also raised prolactin, ACTH and cortisol, and the ACTH and cortisol rise was like that of the stress hormone CRH. The authors called them “not fully specific” (Arvat et al., 1997).
- Other peptides in the family. A 1993 summary from the discoverer’s lab said GHRP-6, GHRP-1 and GHRP-2 were “increasingly more effective” at releasing GH in people, all more than GHRH and all active by mouth. The abstract gives no numbers (Bowers, 1993).
A 30-day infusion in older adults
- Continuous delivery. In 17 healthy older adults, GHRP-2 at 1 microgram per kilogram an hour under the skin for 30 days raised GH secretion more than 3-fold on day 1 and more than 1.8-fold on days 14 and 30. IGF-1 rose to a stable plateau, IGF-binding proteins 3 and 5 rose, and safety screening stayed normal. In 24-hour infusions, adding GHRH gave more GH than either alone (Bowers et al., 2004).
Children
- Injections, 8 months. Six prepubertal children with GH deficiency got 0.3, then 1.0, then 3.0 micrograms per kilogram a day under the skin, each for 2 months. Overnight GH rose with dose but briefly, IGF-1 and IGFBP-3 did not rise, and growth was faster during treatment. No side effects or toxicity were seen (Mericq et al., 1998).
- Nasal spray. Fifteen short children took 5 to 15 micrograms per kilogram twice a day for 3 months, then three times a day. Growth rose from 3.7 to 6.1 cm a year at 6 months, with no significant change in IGF-1 (Pihoker et al., 1997).
- By mouth, 12 months. Ten children with GH deficiency took 900 micrograms per kilogram twice a day. Seven reported more appetite in the first 6 months, and body mass index did not change significantly (Mericq et al., 2003).
Appetite
- Seven lean men. An infusion of 1 microgram per kilogram an hour for 270 minutes raised what they ate at a buffet by 35.9% (range 12 to 95%). They felt hungrier before the meal, GH plateaued near 36 micrograms per litre, cortisol rose briefly, and no side effects were reported (Laferrère et al., 2005).
- Dose and obesity. In 19 people, 10 lean and 9 obese, 0.1 micrograms per kilogram an hour raised intake by 10.2% and 1 microgram per kilogram an hour by 33.5%. Obesity made no difference (Laferrère et al., 2006).
Sleep and critical illness
- Sleep. In seven young men, 1 microgram per kilogram into a vein late in the night raised GH and prolactin and had no effect on slow-wave sleep (Moreno-Reyes et al., 1998).
- Intensive care. In 14 patients critically ill for about 40 days, 5 days of GHRP-2 plus TRH (1 microgram per kilogram an hour of each) raised bone and fat-cell markers (osteocalcin +19% vs −6% on placebo, leptin +32% vs −15%) and brought IGF-1 near normal (Van den Berghe et al., 1999). In 33 men, adding TRH and GnRH to GHRP-2 for 5 days gave stronger hormone and metabolic effects than GHRP-2 alone (Van den Berghe et al., 2002). These trials measured markers, not recovery or survival.
EvidenceCellAnimalHuman
The usual claims, checked
| Claim | Verdict | What the studies found |
|---|---|---|
| It is the strongest of the GHRPs | Untested | It matched hexarelin in the one comparison (Arvat et al., 1997). The 1993 “increasingly more effective” ranking comes from the discoverer’s lab and gives no numbers (Bowers, 1993). We found no independent trial against GHRP-6 |
| It causes less hunger than GHRP-6 | Untested | GHRP-2 raised buffet intake by 35.9% in 7 men and in a dose-related way in 19 (Laferrère et al., 2005; Laferrère et al., 2006). No GHRP-6 trial measured appetite, so nothing supports the comparison (see GHRP-6) |
| It doesn’t raise cortisol or prolactin | Contradicted | It raised both, like hexarelin (Arvat et al., 1997), and cortisol rose in the appetite study (Laferrère et al., 2005) |
| It raises IGF-1 and builds muscle | Mixed | IGF-1 reached a plateau in the 30-day infusion in older adults (Bowers et al., 2004) but did not rise in children over 8 months of injections (Mericq et al., 1998). We found no trial of muscle or body composition (Dominikowski et al., 2026) |
| It improves deep sleep | Contradicted | A late-night injection had no effect on slow-wave sleep (Moreno-Reyes et al., 1998) |
| Results show up in days or weeks | Untested | No study measured such timelines in adults. GH rises within an hour of a dose (Pihoker et al., 1998), and children’s growth rate rose within 6 months (Pihoker et al., 1997) |
| It has no side effects | Mixed | No side effects were reported in the 8-month children’s trial or the 7-man appetite study, and safety screening stayed normal in the 30-day infusion (Mericq et al., 1998; Laferrère et al., 2005; Bowers et al., 2004). The FDA lists serious events with unestablished causes (FDA, 2026) |
| It is an approved drug | Mixed | In Japan only, and only as a 100 microgram single-dose test (Japan drug label). Not for treatment, and not approved in the U.S. |
| It works by mouth or nasal spray | Mixed | Both were tried in children at doses far above the injected ones: 900 micrograms per kilogram twice a day by mouth and 5 to 15 by nasal spray (Mericq et al., 2003; Pihoker et al., 1997) |
Verdict key. Supported: controlled data in people, or the official record, back it. Mixed: studies disagree, or the support is small or limited to one use. Untested: we found no study in people. Contradicted: the studies or record we found show no effect or the opposite.
Side effects and safety
- Hormones. Prolactin, ACTH and cortisol rose after injections (Arvat et al., 1997; Moreno-Reyes et al., 1998).
- Appetite. More hunger and more food eaten, in a dose-related way (Laferrère et al., 2006).
- What the FDA says. For injectable and nasal GHRP-2 it cites the risk of immune reactions from clumping and impurities, and reports of serious events in patients who received it, including a higher insulin requirement, death of critically ill study subjects, infection and pancreatitis. It says causality has not been established (FDA, 2026).
- Pregnancy. The Japanese label contraindicates it (Japan drug label).
- Longest studies. 30 days of infusion in older adults, 8 months of injections in 6 children, and 12 months by mouth in 10 children (Bowers et al., 2004; Mericq et al., 1998; Mericq et al., 2003). We found nothing longer in adults.
- What is in the vial. A lab analysis of black-market growth products found versions of GHRP-2, GHRP-6 and ipamorelin with an extra glycine added at the front (Krug et al., 2018).
Legal and approval status
- Approved in Japan as a test only. The product is a 100 microgram single-dose vial for diagnosing growth hormone deficiency (Japan drug label; KEGG).
- No U.S. product. Drugs@FDA lists no pralmorelin product (openFDA search, no match), and ClinicalTrials.gov lists no study under its names (ClinicalTrials.gov search).
- On the FDA’s compounding lists. GHRP-2 is on the FDA’s safety-risk page for outsourcing facilities, dated September 2023 (FDA, 2026), and in category 3 of its May 2026 compounding categories (FDA list, May 2026).
- Not in the October 2026 HHS policy. That temporary policy covers six other peptides (Reuters, 2026).
- Banned in sport at all times. The World Anti-Doping Agency’s 2026 list names “GHRP-2 (pralmorelin)” under S2, prohibited in and out of competition (WADA, 2026).
- “Research use only” products aren’t approved for use in people.
What to look for if you research it
We don’t name or link sellers. These checks come from the studies and the label:
- Which form? The base is CAS 158861-67-7 and the Japanese product uses the hydrochloride, 158827-34-0 (FDA GSRS; FDA GSRS).
- Not the Japanese product. That product is a 100 microgram test vial under a doctor’s supervision; powders sold online are not it (Japan drug label).
- What is actually in it. Black-market products have been found with glycine-extended versions (Krug et al., 2018). A lab report should confirm the exact sequence.
- Comparisons. A page saying GHRP-2 is “cleaner” or “less hungry” than GHRP-6 should name the trial. We found none.
Our guide to what to look for explains what each test on a lab report proves and which routes are legal; how to read a peptide study explains how to judge the studies sellers cite. For other compounds in this group, see growth hormone secretagogues.
What’s still unknown
- Safety and effects in adults beyond 30 days.
- Whether it builds muscle or changes body composition in any group: no trial measured it.
- How it compares with GHRP-6, hexarelin or ipamorelin in head-to-head trials.
- Whether on-and-off schedules change the response: we found no study.
- What is in the vials and capsules sold online, and whether the form matches the studies.
Retracted and flagged studies
A retracted study has been pulled by its journal, usually for serious errors or misconduct, and its results shouldn’t be relied on. A withdrawn paper was pulled, often before final publication. An expression of concern means the journal has flagged a problem it is still looking into.
We check every study this page cites against PubMed and the Retraction Watch database, and search both for flagged studies that mention GHRP-2. We recheck every month. Last checked Nov 12, 2026.
We found no retracted, withdrawn or flagged studies that mention GHRP-2.
Studies this page relies on
| Study | Published in | Status |
|---|---|---|
| Bowers, 1993 | J Pediatr Endocrinol | No retraction or concern |
| Arvat et al., 1997 | Peptides | No retraction or concern |
| Pihoker et al., 1997 | J Endocrinol | No retraction or concern |
| Pihoker et al., 1998 | J Clin Endocrinol Metab | No retraction or concern |
| Moreno-Reyes et al., 1998 | Am J Physiol | No retraction or concern |
| Mericq et al., 1998 | J Clin Endocrinol Metab | No retraction or concern |
| Van den Berghe et al., 1999 | J Clin Endocrinol Metab | No retraction or concern |
| Van den Berghe et al., 2002 | Clin Endocrinol (Oxf) | No retraction or concern |
| Mericq et al., 2003 | J Pediatr Endocrinol Metab | No retraction or concern |
| Bowers et al., 2004 | J Clin Endocrinol Metab | No retraction or concern |
| Laferrère et al., 2005 | J Clin Endocrinol Metab | No retraction or concern |
| Laferrère et al., 2006 | Obesity (Silver Spring) | No retraction or concern |
| Chihara et al., 2007 | Eur J Endocrinol | No retraction or concern |
| Krug et al., 2018 | Growth Horm IGF Res | No retraction or concern |
| Dominikowski et al., 2026 | Front Endocrinol (Lausanne) | No retraction or concern |
Bring your questions to other researchers
Our forum opens once 100 researchers join the waitlist. Members post studies, ask what they actually found, and answer with sources.
Questions
What is GHRP-2?
A lab-made peptide of six amino acids that copies ghrelin and makes the pituitary release growth hormone. Its one approved product, in Japan, is a single-dose diagnostic test (Laferrère et al., 2005; Japan drug label).
Is GHRP-2 the same as pralmorelin?
Yes. Pralmorelin is its international nonproprietary name (FDA GSRS).
What does GHRP-2 do?
It raised growth hormone, prolactin, ACTH and cortisol, and in infusions it raised appetite (Arvat et al., 1997; Laferrère et al., 2005).
Is GHRP-2 FDA approved?
No. Drugs@FDA lists no product, and no trial is registered (openFDA search, no match; ClinicalTrials.gov search). In Japan it is approved only as a diagnostic test (Japan drug label).
Does GHRP-2 make you hungry?
Yes in studies: buffet intake rose 35.9% in 7 men, and the effect grew with dose (Laferrère et al., 2005; Laferrère et al., 2006).
Does GHRP-2 increase muscle mass?
Not shown. IGF-1 rose in a 30-day infusion in older adults but not in children, and no trial measured muscle (Bowers et al., 2004; Mericq et al., 1998).
What are the side effects of GHRP-2?
Higher prolactin, ACTH and cortisol and more hunger in studies (Arvat et al., 1997; Laferrère et al., 2006).
Is GHRP-2 safe?
We don’t know long term. The longest adult study was 30 days, and the FDA lists serious events with unestablished causes (Bowers et al., 2004; FDA, 2026).
GHRP-2 vs GHRP-6: which is better?
No independent trial compared them. See GHRP-6 for its data; only GHRP-2 has appetite studies (Laferrère et al., 2005).
GHRP-2 vs ipamorelin or hexarelin?
In one trial GHRP-2 matched hexarelin on GH, prolactin, ACTH and cortisol (Arvat et al., 1997). No trial compared it with ipamorelin. See hexarelin.
Does GHRP-2 work by mouth or as a nasal spray?
In children, 900 micrograms per kilogram twice a day by mouth and 5 to 15 by nasal spray were used, far above injected doses (Mericq et al., 2003; Pihoker et al., 1997).
Is GHRP-2 banned in sports?
Yes. The World Anti-Doping Agency lists “GHRP-2 (pralmorelin)” as prohibited at all times (WADA, 2026).
What is the GHRP-2 half-life?
About 33 minutes after a 1 microgram per kilogram injection in ten children (Pihoker et al., 1998).
How long does GHRP-2 take to work?
GH rose within an hour of an injection. No study measured visible results in adults, and children’s growth rate rose within 6 months (Pihoker et al., 1998; Pihoker et al., 1997).
What is the GHRP-2 dosage?
The Japanese test uses 100 micrograms into a vein once (Japan drug label). Studies gave 1 to 2 micrograms per kilogram into a vein, 1 microgram per kilogram an hour under the skin for 270 minutes or 30 days, 0.3 to 3 micrograms per kilogram a day for 2 months at a time, 5 to 15 micrograms per kilogram as a nasal spray twice a day, and 900 micrograms per kilogram by mouth twice a day (Arvat et al., 1997; Bowers et al., 2004; Mericq et al., 1998; Pihoker et al., 1997; Mericq et al., 2003). No study has set a dose for use outside a trial, and we don’t give dosing advice.
Sources
- Chihara K, et al. A simple diagnostic test using GH-releasing peptide-2 in adult GH deficiency. Eur J Endocrinol. 2007;157(1):19-27. PubMed 17609397
- Arvat E, et al. Effects of GHRP-2 and hexarelin, two synthetic GH-releasing peptides, on GH, prolactin, ACTH and cortisol levels in man. Comparison with the effects of GHRH, TRH and hCRH. Peptides. 1997;18(6):885-91. PubMed 9285939
- Bowers CY, et al. Sustained elevation of pulsatile growth hormone (GH) secretion and insulin-like growth factor I (IGF-I), IGF-binding protein-3 (IGFBP-3), and IGFBP-5 concentrations during 30-day continuous subcutaneous infusion of GH-releasing peptide-2 in older men and women. J Clin Endocrinol Metab. 2004;89(5):2290-300. PubMed 15126555
- Mericq V, et al. Effects of eight months treatment with graded doses of a growth hormone (GH)-releasing peptide in GH-deficient children. J Clin Endocrinol Metab. 1998;83(7):2355-60. PubMed 9661608
- Pihoker C, et al. Treatment effects of intranasal growth hormone releasing peptide-2 in children with short stature. J Endocrinol. 1997;155(1):79-86. PubMed 9390009
- Mericq V, et al. Changes in appetite and body weight in response to long-term oral administration of the ghrelin agonist GHRP-2 in growth hormone deficient children. J Pediatr Endocrinol Metab. 2003;16(7):981-5. PubMed 14513874
- Pihoker C, et al. Pharmacokinetics and pharmacodynamics of growth hormone-releasing peptide-2: a phase I study in children. J Clin Endocrinol Metab. 1998;83(4):1168-72. PubMed 9543135
- Laferrère B, et al. Growth hormone releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men. J Clin Endocrinol Metab. 2005;90(2):611-4. PubMed 15699539
- Laferrère B, et al. Obese subjects respond to the stimulatory effect of the ghrelin agonist growth hormone-releasing peptide-2 on food intake. Obesity (Silver Spring). 2006;14(6):1056-63. PubMed 16861611
- Moreno-Reyes R, et al. Evidence against a role for the growth hormone-releasing peptide axis in human slow-wave sleep regulation. Am J Physiol. 1998;274(5):E779-84. PubMed 9612233
- Van den Berghe G, et al. Reactivation of pituitary hormone release and metabolic improvement by infusion of growth hormone-releasing peptide and thyrotropin-releasing hormone in patients with protracted critical illness. J Clin Endocrinol Metab. 1999;84(4):1311-23. PubMed 10199772
- Van den Berghe G, et al. The combined administration of GH-releasing peptide-2 (GHRP-2), TRH and GnRH to men with prolonged critical illness evokes superior endocrine and metabolic effects compared to treatment with GHRP-2 alone. Clin Endocrinol (Oxf). 2002;56(5):655-69. PubMed 12030918
- Bowers CY. GH releasing peptides--structure and kinetics. J Pediatr Endocrinol. 1993;6(1):21-31. PubMed 8374685
- Krug O, et al. Analysis of new growth promoting black market products. Growth Horm IGF Res. 2018;41:1-6. PubMed 29864719
- Dominikowski A, et al. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. Front Endocrinol (Lausanne). 2026;17:1822475. PubMed 42395176
- Pharmaceuticals and Medical Devices Agency (Japan). GHRP KAKEN100 Injection (pralmorelin hydrochloride), package insert, 3rd edition, July 2025. Japan drug label
- Kanehisa Laboratories. KEGG DRUG: Pralmorelin hydrochloride (D02040). KEGG entry
- ClinicalTrials.gov. Searches for GHRP-2 and pralmorelin, November 12, 2026: no studies. Search
- U.S. Food and Drug Administration. Drugs@FDA data via openFDA, searched November 12, 2026: no pralmorelin product or label. openFDA search, no match
- U.S. Food and Drug Administration. Safety risks associated with certain bulk drug substances nominated for use in compounding. Content current as of April 22, 2026. FDA page
- U.S. Food and Drug Administration. Bulk drug substances nominated for use in compounding under section 503A. Updated May 14, 2026. FDA document
- World Anti-Doping Agency. 2026 Prohibited List, section S2.2.4. WADA document
- Reuters. U.S. health department to allow temporary sale of some unapproved peptides. October 28, 2026. Article
- U.S. Food and Drug Administration. Global Substance Registration System: PRALMORELIN (UNII E6S6E1F19M). GSRS
- U.S. Food and Drug Administration. Global Substance Registration System: PRALMORELIN DIHYDROCHLORIDE (UNII R4AVR27MM8). GSRS
Last reviewed Nov 12, 2026. Approval and compounding status change often; we recheck this page when they do. Nothing here is medical advice; see our medical disclaimer. Found a mistake? Email editors@peptideresearchstudy.com.